BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 13/02/2015

FDA Clears SUBUTEX Sublingual Tablets for Continued Sale

The FDA has determined that SUBUTEX Sublingual Tablets, containing 2mg and 8mg of buprenorphine hydrochloride, were not withdrawn from sale due to safety or effectiveness concerns, allowing the tablets to remain on the market.

Source: Federal Register — Food and Drug AdministrationOpen original release →